Chartwell Partners is pleased to announce the appointment of Paula Cobb to the Board of Directors for Prothena, a clinical stage neuroscience company focused on developing therapies for some of the most debilitating neurological diseases. Paula brings a tremendous breadth of experience overseeing portfolio strategy, program management, product development and commercialization for multiple specialty and rare disease therapeutics across the US and Europe. She currently serves as the Chief Operating Officer for Decibel Therapeutics, a clinical-stage biotechnology company focused on developing novel therapeutics for hearing and balance disorders. Previously, she spent 13 years with Biogen and began her career in management consulting. Until its acquisition by Biogen, Paula served on the Board of Directors for Nightstar Therapeutics plc, a clinical-stage gene therapy company.
Official press release from Prothena – http://ir.prothena.com/news-releases/news-release-details/prothena-announces-appointment-paula-k-cobb-its-board-directors